La chaîne d'options affiche les données clés des options sur actions de Ensysce Biosciences à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Ensysce Biosciences..

Ensysce Biosciences (NASDAQ:ENSC) Stock, Chaîne d'Options

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

News

Press Releases

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Events

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Earnings

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Analyst Ratings

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

ENSC

AIM ImmunoTech

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

GT Biopharma

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

SILO Pharma

Alaunos Therapeutics, Inc. - Common Stock

Comments

Ensysce Biosciences

Ensysce Biosciences (ENSC) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL